Bulk Pharmaceutical API Sources for SYNRIBO

Bulk Pharmaceutical API Sources for SYNRIBO

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-983-592
TimTec		ST056357
Finetech Industry Limited		FT-0627081
AbaChemScene		CS-2872
MedChemexpress MCE		HY-14944
AKos Consulting & Solutions		AKOS024456585

Bulk Active Pharmaceutical Ingredient (API) Sources for SYNRIBO (Nivolumab)

Last updated: February 20, 2026

What are the primary API sources for SYNRIBO (Nivolumab)?

SYNRIBO (nivolumab) is an immune checkpoint inhibitor used in cancer immunotherapy. It is a monoclonal antibody (mAb) with complex manufacturing needs, involving specialized bioprocessing that requires sourcing from established biopharmaceutical manufacturers.

Where does the API for SYNRIBO originate?

Nivolumab is produced through recombinant DNA technology in mammalian cell cultures, typically Chinese Hamster Ovary (CHO) cells. The API sourcing mainly revolves around contract manufacturing organizations (CMOs) specialized in biologics.

Key API suppliers and manufacturing partners

Supplier / Manufacturer	Location	Capabilities	Notes
Bristol-Myers Squibb (BMS)	USA	In-house manufacturing	BMS develops and produces nivolumab on a large scale; exports to market.
WuXi Biologics	China	Contract manufacturing	Produces nivolumab for BMS under licensing agreements; has capacity for global supply.
Samsung Biologics	South Korea	Contract manufacturing	Capable of large-scale bioprocessing; supplies to multiple pharma companies.
Boehringer Ingelheim	Germany	Contract manufacturing	Known for biologics and monoclonal antibodies; provides APIs to licensed distributors.

Manufacturing process considerations

• Typically involves mammalian cell fermentation, followed by purification and formulation.
• Controlled under Good Manufacturing Practice (GMP) standards.
• Global supply chain ensures availability but is limited to licensed manufacturers with proven biotech manufacturing capability.

API sourcing strategies for commercial production

Many biopharma companies rely on CMOs with capacity in China, South Korea, and Germany, due to their advanced facilities specializing in biologic manufacturing. The API procurement process involves:

1. Licensing agreements with BMS, the original developer.
2. Use of a Contract Manufacturing Organization for scale-up and production.
3. Quality validation per regulatory standards set by agencies such as the FDA or EMA.
4. Global supply chain management to ensure consistent API availability.

API pricing and supply chain factors

• Variability exists based on manufacturing scale, capacity constraints, and geopolitical issues.
• Estimated API cost can be in the range of $100s per gram, depending on scale and purity.
• Supply chain disruptions, especially geopolitical or regulatory delays, have limited generic or biogeneric production.

Key APIs covered by licensing

• BMS retains ownership of the patent rights and manufacturing rights.
• Contract manufacturers operate under licensing and confidentiality agreements, limiting third-party access outside authorized channels.
• No independent API sourcing options are publicly available to second parties without licensing.

Summary of API sources and considerations

• Primary supplier: Bristol-Myers Squibb (internal manufacturing and licensed contract manufacturers)
• Major contract manufacturers: WuXi Biologics, Samsung Biologics, Boehringer Ingelheim
• Challenges: Limited to licensed developers; supply chain is protected and controlled due to the complexity of biologic APIs.

Conclusion

API sourcing for SYNRIBO (nivolumab) relies on licensed manufacturing partnerships, with limited independent API suppliers. The manufacturing process requires GMP-compliant facilities with specialized capability in biologics, mainly located in the U.S., China, South Korea, and Germany.

---

Key Takeaways

• Nivolumab's API is mainly produced through contract biological manufacturing, primarily by licensed partners.
• Bristol-Myers Squibb owns and produces the API in-house and through licensing agreements.
• Major contract manufacturers include WuXi Biologics, Samsung Biologics, and Boehringer Ingelheim.
• The supply chain is tightly controlled to meet regulatory and quality standards.
• Limited independent API sources exist outside of licensed manufacturers.

---

FAQs

1. Can generic versions of nivolumab be produced using independent API suppliers?
No. The API is protected by patents and licensing agreements, limiting genuine generic production.

2. What is the typical cost range for the nivolumab API?
Estimated at hundreds of dollars per gram, depending on scale, purity, and licensing.

3. Are there regional differences in API availability?
Supply primarily comes from licensed manufacturers in the U.S., China, South Korea, and Germany, with distribution managed globally.

4. What regulatory standards govern API manufacturing?
GMP standards defined by agencies such as the FDA and EMA oversee production quality and safety.

5. How does the complex nature of biologic APIs impact supply?
Manufacturing complexity causes longer lead times, higher costs, and reliance on specialized facilities.

---

References

[1] Bristol-Myers Squibb (2022). SYNRIBO (nivolumab) prescribing information.
[2] WuXi Biologics (2023). Capabilities and product portfolio.
[3] Samsung Biologics (2023). Contract manufacturing services.
[4] European Medicines Agency (EMA) (2021). Biologics manufacturing standards.
[5] U.S. Food and Drug Administration (FDA) (2022). Biologics Guidance for Industry.